Neurocrine Biosciences develops and commercializes medicines for neurological, neuroendocrine and rare disorders that often lack adequate treatment options. Its best-known product is INGREZZA (valbenazine), used for tardive dyskinesia and chorea associated with Huntington’s disease. The broader portfolio and pipeline also span conditions such as congenital adrenal hyperplasia, Prader-Willi hyperphagia and women’s health indications, often advanced through focused discovery and selective partnerships.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 687.5 | — | 107.5 | -34.5% |
| Q3 2025 | 794.9 | — | 209.5 | 13.8% |
| Q4 2025 | 805.5 | — | 153.7 | -10.2% |
| Q1 2026 | 814.5 | — | 197.9 | 183.6% |
| Q2 2026 | 959 | 39.5% | 144.4 | 34.3% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Regency Centers Corporation (REG), Jazz Pharmaceuticals plc (JAZZ), Ares Capital Corporation (ARCC), ICON Public Limited Company (ICLR), CoStar Group, Inc. (CSGP), Sterling Infrastructure, Inc. (STRL)